View Older Stories
-
Elevance (ELV) PT Lowered to $409 at Bernstein
-
Elevance Health flags earnings decline amid bleak Medicare Advantage proposal
-
Elevance Health Inc. (ELV) Tops Q4 EPS by 23c; offers outlook
-
Health insurers slide after 2027 Medicare Advantage payments proposal underwhelms
-
Elevance Health (ELV) call put ratio 1 call to 1 put
-
After-hours movers: Humana, UnitedHealth, CVS Health, Sanmina and more
-
Elevance (ELV) PT Raised to $414 at Guggenheim
-
Bernstein: Softening Safety Net Cuts Signal Tailwinds for Medicaid and Marketplace Names (CNC, MOH, ELV)
-
Wolfe Research Upgrades Elevance (ELV) to Outperform
-
Elevance (ELV) Reiterated at Overweight by Cantor Fitzgerald
-
Deutsche Bank Downgrades Elevance (ELV) to Hold
-
Elevance (ELV) PT Raised to $400 at TD Cowen, 'Best Ideas 2026'
-
Elevance Health (ELV) CFO sees Medicaid margin declining at least 125 bps in '26
-
Elevance (ELV) PT Lowered to $400 at Mizuho
-
Elevance (ELV) PT Lowered to $412 at Bernstein SocGen Group
-
Cantor Fitzgerald Reiterates Elevance (ELV) at Overweight: Cautious of '26 Medicaid Environment
-
Elevance (ELV) PT Raised to $350 at Leerink Partners
-
Bernstein SocGen Group Reiterates Outperform Rating on Elevance (ELV)
-
Elevance Health Inc. (ELV) Tops Q3 EPS by 108c
-
Elevance Health earnings preview: Wolfe sees conservative 2026 guidance as potential ‘bottom’
-
Elevance Health (ELV) call put ratio 2.6 calls to 1 put into quarter results
-
Elevance (ELV) PT Lowered to $420 at Bernstein SocGen Group
-
Cantor Fitzgerald Reiterates Neutral on Molina Healthcare (MOH), Highlights 2026 Stars Progress
-
Cantor Fitzgerald Reiterates Overweight on Elevance (ELV), Cites 5-Star Membership Growth
-
Mizuho Positive on CVS Health (CVS): 'We believe this is a positive for CVS'
-
Elevance (ELV) PT Raised to $398 at Guggenheim
-
Cantor Fitzgerald Reiterates Neutral Rating on Humana (HUM)
-
Cantor Fitzgerald Reiterates Overweight Rating on Elevance (ELV)
-
Cantor Fitzgerald Reiterates Neutral Rating on Centene (CNC)
-
Important Notice to Long-term Shareholders of Elevance Health Inc. (ELV): Grabar Law Office Investigates Claims on Your Behalf
-
Cantor Fitzgerald Reiterates Overweight Rating on UnitedHealth Group (UNH)
-
Cantor Fitzgerald Reiterates Overweight Rating on Tenet Healthcare (THC)
-
Cantor Fitzgerald Reiterates Overweight Rating on Elevance (ELV)
-
Cantor Fitzgerald Reiterates Overweight Rating on CIGNA (CI)
-
Grabar Law Office Investigates Claims on Behalf of Shareholders of Elevance Health Inc. (ELV)
-
UnitedHealth projects most Medicare Advantage members in top-rated plans by 2027
-
UnitedHealth Group (UNH) PT Raised to $379 at Bernstein
-
Elevance Health reaffirms 2025 earnings guidance of $24.10 per share
-
Elevance Health appoints Steve Collis to board of directors
-
UBS Reiterates Buy Rating on Elevance (ELV)
-
Elevance (ELV) PT Lowered at Bernstein, Citing '2025 Pressures and Slower Recovery in Medicaid'
-
Argus Downgrades Elevance (ELV) to Hold
-
Elevance (ELV) PT Lowered to $330 at TD Cowen
-
Elevance Health (ELV) options active amid wide price movement
-
Elevance (ELV) PT Lowered to $435 at UBS
-
Cantor Fitzgerald Reiterates Overweight Rating on Elevance (ELV)
-
Elevance (ELV) PT Lowered to $360 at Guggenheim
-
Increasing unusual option volume: HUYA OPEN ELV REPL ABAT CX CMA GNW
-
Leerink Partners Downgrades Elevance (ELV) to Market Perform
-
Elevance (ELV) PT Lowered to $350 at BofA Securities

